# Patient-Trial Match Report

*Generated: 2026-01-05 06:58:20*

## Patient Profile

- **Age**: 71
- **Sex**: Male
- **Cancer Type**: squamous cell lung cancer

**Clinical Description**:
> 71-year-old male with metastatic squamous cell lung cancer, no actionable driver mutations identified (EGFR/ALK/ROS1/BRAF wild-type, KRAS wild-type). PD-L1 TPS â‰¥90%. First-line pembrolizumab monotherapy achieved durable response for 22 months, now progressed with new contralateral lung nodules and mediastinal lymphadenopathy. Seeking second-line immunotherapy combinations or novel checkpoint approaches. Former heavy smoker (50 pack-years). COPD on inhalers, no supplemental O2. Mild CKD (eGFR 52). Motivated patient willing to travel for trials.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 7
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 98
- **LLM scored**: 2

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient is male and â‰¥ 18 years old
- Patient has a squamous cell lung cancer
- ECOG status of 1
- Patient has advanced solid tumors that have progressed after prior treatment

**? Uncertainties:**
- Laboratory values for adequate hematological, hepatic, and renal function are not provided
- Patient's life expectancy not explicitly stated

**Assessment:**
> The patient's cancer type matches the trial conditions as he has squamous cell lung cancer. He is a previously treated patient, which is acceptable according to trial criteria. However, there are uncertainties regarding organ function labs and life expectancy that need verification for a conclusive eligibility assessment.

---

## Excluded (99 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT03476681](https://clinicaltrials.gov/study/NCT03476681) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03586453](https://clinicaltrials.gov/study/NCT03586453) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04093167](https://clinicaltrials.gov/study/NCT04093167) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04253964](https://clinicaltrials.gov/study/NCT04253964) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04317534](https://clinicaltrials.gov/study/NCT04317534) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04486833](https://clinicaltrials.gov/study/NCT04486833) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04499053](https://clinicaltrials.gov/study/NCT04499053) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04585477](https://clinicaltrials.gov/study/NCT04585477) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04868877](https://clinicaltrials.gov/study/NCT04868877) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04892953](https://clinicaltrials.gov/study/NCT04892953) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04991025](https://clinicaltrials.gov/study/NCT04991025) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05094336](https://clinicaltrials.gov/study/NCT05094336) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05098132](https://clinicaltrials.gov/study/NCT05098132) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05118854](https://clinicaltrials.gov/study/NCT05118854) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05121051](https://clinicaltrials.gov/study/NCT05121051) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05123482](https://clinicaltrials.gov/study/NCT05123482) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05168566](https://clinicaltrials.gov/study/NCT05168566) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05261399](https://clinicaltrials.gov/study/NCT05261399) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 78 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05566223](https://clinicaltrials.gov/study/NCT05566223) | Intima Bioscience, I | Age 71 does not meet the eligibility criterion of age â‰¤ 70 years. |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| squamous cell lung cancer | manual | 1.0 |
| PD-L1 TPS â‰¥90% squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS â‰¥90% metastatic squamous cell lung cancer | llm | 0.9 |
| PD-L1 TPS â‰¥90% NSCLC | llm | 0.9 |
| metastatic squamous cell lung cancer | llm | 0.8 |
| NSCLC | llm | 0.8 |
| PD-L1 TPS â‰¥90% | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Life expectancy estimate** - many trials require â‰¥3 months
